Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinhua Miyanjing Tablet is a Traditional Chinese Medicine (TCM) formulation developed by Jilin Huakang Pharmaceutical for the treatment of genitourinary conditions, specifically chronic prostatitis (Type III) and urinary tract infections. The preparation is designed to address the TCM pattern of 'damp-heat pouring downward' (湿热下注), which is associated with symptoms such as urinary frequency, urgency, and pelvic pain. It is a multi-herb combination typically containing botanical extracts such as *Lonicera japonica* (honeysuckle), *Polygonum aviculare* (knotgrass), *Dianthus superbus* (fringed pink), *Plantago asiatica* (plantain), and *Gardenia jasminoides* (gardenia). These ingredients are traditionally recognized for their heat-clearing, detoxifying, and diuretic properties. The drug has been evaluated in Phase 3 clinical trials in China (e.g., CTR20160209) to assess its efficacy and safety compared to placebo and active controls in men with chronic pelvic pain syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinhua Miyanjing Tablet.